As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.

GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.

As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.